Asset Publisher Asset Publisher


Are different SARS-CoV-2 serological assays comparable?


Publication by a partner with biobank involvement


Comparison of automated SARS-CoV-2 serology assays in assessing virus neutralization capacity


Arch Pathol Lab Med. 2022, Feb 2022             

                                              partner Biobank Graz together with researchers at Med Uni Graz, have established several different COVID-19-related sample cohorts. One of these, the "COVID-19 Convalescent Cohort", the researchers and biobankers used in a study on the comparison of automated SARS-CoV-2 serology assays. A scientific paper is now published in Arch Pathol Lab Med., Feb 2022.


Serological tests on automated immunology analyzers used to monitor the acquired immunity against SARS-CoV-2 often show heterogeneous results. Researchers from partner Med Uni Graz with Biobank Graz involvement, therefore, analysed six different SARS-CoV-2 serology assays concerning their diagnostic performance and comparability in sera from COVID-19 convalescents.


The results revealed that the different serological SARS-CoV-2 antibody tests were poorly comparable. Biggest discrepancies were observed in detecting antibody titer changes.


However, these tests are still a reliable surrogate test for SARS-CoV-2 neutralizing antibodies in patients recovered from COVID-19 with an appropriate validation.



Read details in the original article>


Niedrist T, Drexler C, Torreiter PP, Matejka J, Strahlhofer-Augsten M, Kral S, Riegler S, Gülly C, Zurl C, Kriegl L, Krause R, Berghold A, Steinmetz I, Schlenke P, Herrmann M.

Longitudinal comparison of automated SARS-CoV-2 serology assays in assessing virus neutralization capacity in COVID-19 convalescent sera.

Arch Pathol Lab Med. 2022 Jan 27. doi: 10.5858/arpa.2021-0604-SA. Epub ahead of print. PMID: 35085385.